- Home
- All Stock List
- BSE
- Divis Laboratories Ltd Share Price
6,612.15
-21.35 (-0.32%)
-
Outperforms Index
49.86%
Return (1Y)
Beaten BSE Healthcare by 30.35%
-
More Volatile
1.92%
Standard Deviation (1Y)
Higher than BSE Healthcare by 0.85%
-
Consistent Performer
7/12
Months
beaten BSE Healthcare
-
AxisDirect View
No View
6,764
4,183
News & Announcements
-
Divis Lab enters into a LT manufacturing and supply agreement with a global pharma co.
24 - May - 2025 12:00 | 8 days ago
Divis Laboratories has entered into a long term manufacturing and supply agreement with a global pharma company.
Under this agreement, the Company will be manufacturing and supplying advanced intermediates as per the commercial terms agreed between the parties.
The Company expects meaningful revenue contribution from this long-term agreement.
Cost of capacity addition for manufacturing under this agreement is estimated to be Rs.650-750 crore, which will be funded from the capacity reservation advance proposed to be paid by the customer phase wise under this Agreement.
Powered by Capital Market - Live News
-
Divis Lab inks long-term global pharma deal
8 days ago
As part of the agreement, Divis will manufacture and supply advanced pharmaceutical intermediates to the global partner. The company has stated that the contract is expected to contribute meaningfully to its revenue over the long term.
To support the execution of this deal, Divis plans to invest between Rs 650 crore and Rs 750 crore to expand its manufacturing capacity. This investment will be funded through capacity reservation advances that will be paid in phases by the customer.
Divis Laboratories believes the partnership will not only ensure a reliable supply chain for the customer but also allow the company to strengthen its foothold in the custom synthesis space.
The company clarified that the deal does not involve any share exchange or related party transactions. There is no involvement of the promoter group or affiliated companies in the agreement.
Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. The company's consolidated net profit jumped 23.04% to Rs 662 crore while revenue from operations grew by 12.24% to Rs 2,585 crore in Q4 March 2025 over Q4 March 2024.
Powered by Capital Market - Live News
-
Divis Laboratories to convene AGM
13 days ago
-
Divis Lab inks long-term global pharma deal
8 days ago
As part of the agreement, Divis will manufacture and supply advanced pharmaceutical intermediates to the global partner. The company has stated that the contract is expected to contribute meaningfully to its revenue over the long term.
To support the execution of this deal, Divis plans to invest between Rs 650 crore and Rs 750 crore to expand its manufacturing capacity. This investment will be funded through capacity reservation advances that will be paid in phases by the customer.
Divis Laboratories believes the partnership will not only ensure a reliable supply chain for the customer but also allow the company to strengthen its foothold in the custom synthesis space.
The company clarified that the deal does not involve any share exchange or related party transactions. There is no involvement of the promoter group or affiliated companies in the agreement.
Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. The company's consolidated net profit jumped 23.04% to Rs 662 crore while revenue from operations grew by 12.24% to Rs 2,585 crore in Q4 March 2025 over Q4 March 2024.
Powered by Capital Market - Live News
-
Divis Laboratories to convene AGM
13 days ago
-
Divis Lab gains after Q4 PAT climbs 23% YoY; recommends final dividend of Rs 30/ share
19 - May - 2025 12:00 | 13 days ago
Revenue from operations grew by 12.24% year on year (YoY) to Rs 2,585 crore in the quarter ended 31 March 2025.
Profit before tax for the quarter was at Rs 864 crore, up 21.17% from Rs 713 crore reported in the same period a year ago.
Total expense stood at Rs 1,807 crore in Q4 FY25, up 8.26% on a YoY basis. The cost of material consumed was Rs 931 crore (up 3.67% YoY) and employee benefit expenses stood at Rs 350 crore (up 17.84% YoY) during the period under review.
The company reported a forex gain of Rs 10 crore in Q4 FY25, compared to a loss of Rs 2 crore in Q4 FY24.
On a standalone basis, the company?s net profit surged 25.61% to Rs 667 crore on a 12.26% rise in revenue to Rs 2,536 crore in Q4 FY25 over Q4 FY24.
For the financial year ended 31 March 2025, the company?s consolidated net profit rose 36.93% YoY to Rs 2,191 crore. Revenue from operations grew 19.31% YoY to Rs 9,360 crore, compared to FY24.
On the capex front, the company stated that the Unit III greenfield project at Ontimamidi Village, near Kakinada, Andhra Pradesh, commenced commercial operations during the current quarter. The company capitalised assets worth Rs 1,118 crore during the financial year, of which Rs 755 crore pertained to Unit III at Kakinada.
Meanwhile, the company?s board has recommended a dividend of Rs 30 per equity share for the financial year 2024?25, subject to approval by the members at the upcoming Annual General Meeting.
Further, the company?s board has approved the superannuation of L. Kishore Babu, Chief Financial Officer and Key Managerial Personnel, effective from 1 August 2025. The board placed on record its appreciation for Babu?s contributions and leadership at Divi?s Labs.
Furthermore, the board has approved the appointment of Venkatesa Perumallu Pasumarthy as chief financial officer and key managerial personnel, also effective 1 August 2025. The appointment was recommended by the Nomination and Remuneration Committee and the Audit Committee of the company.
Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients.
Powered by Capital Market - Live News
-
Divis Lab enters into a LT manufacturing and supply agreement with a global pharma co.
24 - May - 2025 12:00 | 8 days ago
Divis Laboratories has entered into a long term manufacturing and supply agreement with a global pharma company.
Under this agreement, the Company will be manufacturing and supplying advanced intermediates as per the commercial terms agreed between the parties.
The Company expects meaningful revenue contribution from this long-term agreement.
Cost of capacity addition for manufacturing under this agreement is estimated to be Rs.650-750 crore, which will be funded from the capacity reservation advance proposed to be paid by the customer phase wise under this Agreement.
Powered by Capital Market - Live News
-
Divis Lab inks long-term global pharma deal
8 days ago
As part of the agreement, Divis will manufacture and supply advanced pharmaceutical intermediates to the global partner. The company has stated that the contract is expected to contribute meaningfully to its revenue over the long term.
To support the execution of this deal, Divis plans to invest between Rs 650 crore and Rs 750 crore to expand its manufacturing capacity. This investment will be funded through capacity reservation advances that will be paid in phases by the customer.
Divis Laboratories believes the partnership will not only ensure a reliable supply chain for the customer but also allow the company to strengthen its foothold in the custom synthesis space.
The company clarified that the deal does not involve any share exchange or related party transactions. There is no involvement of the promoter group or affiliated companies in the agreement.
Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. The company's consolidated net profit jumped 23.04% to Rs 662 crore while revenue from operations grew by 12.24% to Rs 2,585 crore in Q4 March 2025 over Q4 March 2024.
Powered by Capital Market - Live News
-
Divis Laboratories to convene AGM
13 days ago
-
Divis Lab gains after Q4 PAT climbs 23% YoY; recommends final dividend of Rs 30/ share
19 - May - 2025 12:00 | 13 days ago
Revenue from operations grew by 12.24% year on year (YoY) to Rs 2,585 crore in the quarter ended 31 March 2025.
Profit before tax for the quarter was at Rs 864 crore, up 21.17% from Rs 713 crore reported in the same period a year ago.
Total expense stood at Rs 1,807 crore in Q4 FY25, up 8.26% on a YoY basis. The cost of material consumed was Rs 931 crore (up 3.67% YoY) and employee benefit expenses stood at Rs 350 crore (up 17.84% YoY) during the period under review.
The company reported a forex gain of Rs 10 crore in Q4 FY25, compared to a loss of Rs 2 crore in Q4 FY24.
On a standalone basis, the company?s net profit surged 25.61% to Rs 667 crore on a 12.26% rise in revenue to Rs 2,536 crore in Q4 FY25 over Q4 FY24.
For the financial year ended 31 March 2025, the company?s consolidated net profit rose 36.93% YoY to Rs 2,191 crore. Revenue from operations grew 19.31% YoY to Rs 9,360 crore, compared to FY24.
On the capex front, the company stated that the Unit III greenfield project at Ontimamidi Village, near Kakinada, Andhra Pradesh, commenced commercial operations during the current quarter. The company capitalised assets worth Rs 1,118 crore during the financial year, of which Rs 755 crore pertained to Unit III at Kakinada.
Meanwhile, the company?s board has recommended a dividend of Rs 30 per equity share for the financial year 2024?25, subject to approval by the members at the upcoming Annual General Meeting.
Further, the company?s board has approved the superannuation of L. Kishore Babu, Chief Financial Officer and Key Managerial Personnel, effective from 1 August 2025. The board placed on record its appreciation for Babu?s contributions and leadership at Divi?s Labs.
Furthermore, the board has approved the appointment of Venkatesa Perumallu Pasumarthy as chief financial officer and key managerial personnel, also effective 1 August 2025. The appointment was recommended by the Nomination and Remuneration Committee and the Audit Committee of the company.
Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients.
Powered by Capital Market - Live News
-
Divis Lab enters into a LT manufacturing and supply agreement with a global pharma co.
24 - May - 2025 12:00 | 8 days ago
Divis Laboratories has entered into a long term manufacturing and supply agreement with a global pharma company.
Under this agreement, the Company will be manufacturing and supplying advanced intermediates as per the commercial terms agreed between the parties.
The Company expects meaningful revenue contribution from this long-term agreement.
Cost of capacity addition for manufacturing under this agreement is estimated to be Rs.650-750 crore, which will be funded from the capacity reservation advance proposed to be paid by the customer phase wise under this Agreement.
Powered by Capital Market - Live News
-
Divis Lab inks long-term global pharma deal
8 days ago
As part of the agreement, Divis will manufacture and supply advanced pharmaceutical intermediates to the global partner. The company has stated that the contract is expected to contribute meaningfully to its revenue over the long term.
To support the execution of this deal, Divis plans to invest between Rs 650 crore and Rs 750 crore to expand its manufacturing capacity. This investment will be funded through capacity reservation advances that will be paid in phases by the customer.
Divis Laboratories believes the partnership will not only ensure a reliable supply chain for the customer but also allow the company to strengthen its foothold in the custom synthesis space.
The company clarified that the deal does not involve any share exchange or related party transactions. There is no involvement of the promoter group or affiliated companies in the agreement.
Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. The company's consolidated net profit jumped 23.04% to Rs 662 crore while revenue from operations grew by 12.24% to Rs 2,585 crore in Q4 March 2025 over Q4 March 2024.
Powered by Capital Market - Live News
-
Divis Laboratories to convene AGM
13 days ago
-
Divis Lab inks long-term global pharma deal
8 days ago
As part of the agreement, Divis will manufacture and supply advanced pharmaceutical intermediates to the global partner. The company has stated that the contract is expected to contribute meaningfully to its revenue over the long term.
To support the execution of this deal, Divis plans to invest between Rs 650 crore and Rs 750 crore to expand its manufacturing capacity. This investment will be funded through capacity reservation advances that will be paid in phases by the customer.
Divis Laboratories believes the partnership will not only ensure a reliable supply chain for the customer but also allow the company to strengthen its foothold in the custom synthesis space.
The company clarified that the deal does not involve any share exchange or related party transactions. There is no involvement of the promoter group or affiliated companies in the agreement.
Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. The company's consolidated net profit jumped 23.04% to Rs 662 crore while revenue from operations grew by 12.24% to Rs 2,585 crore in Q4 March 2025 over Q4 March 2024.
Powered by Capital Market - Live News
-
Divis Laboratories to convene AGM
13 days ago
-
Divis Lab gains after Q4 PAT climbs 23% YoY; recommends final dividend of Rs 30/ share
19 - May - 2025 12:00 | 13 days ago
Revenue from operations grew by 12.24% year on year (YoY) to Rs 2,585 crore in the quarter ended 31 March 2025.
Profit before tax for the quarter was at Rs 864 crore, up 21.17% from Rs 713 crore reported in the same period a year ago.
Total expense stood at Rs 1,807 crore in Q4 FY25, up 8.26% on a YoY basis. The cost of material consumed was Rs 931 crore (up 3.67% YoY) and employee benefit expenses stood at Rs 350 crore (up 17.84% YoY) during the period under review.
The company reported a forex gain of Rs 10 crore in Q4 FY25, compared to a loss of Rs 2 crore in Q4 FY24.
On a standalone basis, the company?s net profit surged 25.61% to Rs 667 crore on a 12.26% rise in revenue to Rs 2,536 crore in Q4 FY25 over Q4 FY24.
For the financial year ended 31 March 2025, the company?s consolidated net profit rose 36.93% YoY to Rs 2,191 crore. Revenue from operations grew 19.31% YoY to Rs 9,360 crore, compared to FY24.
On the capex front, the company stated that the Unit III greenfield project at Ontimamidi Village, near Kakinada, Andhra Pradesh, commenced commercial operations during the current quarter. The company capitalised assets worth Rs 1,118 crore during the financial year, of which Rs 755 crore pertained to Unit III at Kakinada.
Meanwhile, the company?s board has recommended a dividend of Rs 30 per equity share for the financial year 2024?25, subject to approval by the members at the upcoming Annual General Meeting.
Further, the company?s board has approved the superannuation of L. Kishore Babu, Chief Financial Officer and Key Managerial Personnel, effective from 1 August 2025. The board placed on record its appreciation for Babu?s contributions and leadership at Divi?s Labs.
Furthermore, the board has approved the appointment of Venkatesa Perumallu Pasumarthy as chief financial officer and key managerial personnel, also effective 1 August 2025. The appointment was recommended by the Nomination and Remuneration Committee and the Audit Committee of the company.
Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients.
Powered by Capital Market - Live News
Stock Trivia
Divis Laboratories Ltd is trading very close to its All time High
GovT shareholding in Divis Laboratories Ltd has increased by 50% since past 3 Months
Divis Laboratories Ltd is trading very close to its All time High
Divis Laboratories Ltd is trading very close to its 52 Week High
MF shareholding in Divis Laboratories Ltd has increased by 7.87% since past 3 Months
GovT shareholding in Divis Laboratories Ltd has increased by 50% since past 3 Months
Divis Laboratories Ltd is trading very close to its All time High
GovT shareholding in Divis Laboratories Ltd has increased by 50% since past 3 Months
